A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer

By sjmartinez • February 15, 2024

Riely GJ, Smit EF, Ahn MJ, Felip E, Ramalingam SS, Tsao A, Johnson M, Gelsomino F, Esper R, Nadal E, Offin M, Provencio M, Clarke J, Hussein M, Otterson GA, Dagogo-Jack I, Goldman JW, Morgensztern D, Alcasid A, Usari T, Wissel P, Wilner K, Pathan N, Tonkovyd S, Johnson BE. A plain language summary of the PHAROS study: the combination of encorafenib and binimetinib for people with BRAF V600E-mutant metastatic non-small cell lung cancer. Future Oncol. 2024 Feb 15. doi: 10.2217/fon-2023-0859. Epub ahead of print. PMID: 38357801.

Tags: encorafenib plus binimetinib, Hematology/Oncology, Non-small cell lung cancer, PHAROS, plain language summary

Galectin-1 modulates glycolysis via a GM1-galactose-dependent pathway to promote hyperthermia resistance in hepatocellular carcinoma

Nguyen T, Shin Y, Ruppa A, Krall AS, Pham J, Chen PC, Mirmohammadi H, Keshavarz P, Finn RS, Agopian VG, French SW, Christofk HR, Lu[...]

Treatment Patterns of Goserelin 3.6 mg Once Every 4 Weeks and 10.8 mg Once Every 12 Weeks in Women With Breast Cancer: A Real-World Analysis of Patients in the United States

McCann KE, Kaklamani V, Osman N, Cannon J, Brent L, Lucia R, Li C, Duran N, Gupta S, Martin N. Treatment Patterns of Goserelin 3.6[...]

Neoadjuvant Chemotherapy Is Associated With Reduced Amputation Risk in Synovial Sarcoma of the Lower Extremity

Wahle CF, Newman-Hung NJ, Sakowitz S, Federman N, Singh AS, Bernthal NM, Benharash P, Wessel LE. Neoadjuvant Chemotherapy Is Associated With Reduced Amputation Risk in[...]